Characterization of the inhibitory effects of transforming growth factor-beta on a human colon carcinoma cell line.
The effects of transforming growth factor-beta (TGF beta) on a human colon carcinoma cell line (MOSER) were investigated. TGF beta, at low concentrations (between 0.1 and 1.0 ng/ml), inhibited the proliferation of MOSER cells both in monolayer culture and soft agarose, in a dose-dependent manner. MOSER cells adapted to growth in chemically defined serum-free medium were more sensitive to the inhibitory effects of TGF beta than cells maintained in serum-supplemented medium. Morphological changes in MOSER cells, observed with TGF beta, were similar to those seen with the chemical differentiation agent N,N-dimethylformamide. Also in similarity to the effects of N,N-dimethylformamide, TGF beta induced a time- and concentration-dependent increase in soluble extracellular fibronectin. Binding studies with [125I]TGF beta revealed a relatively low number of binding sites on MOSER cells (13%) compared with mouse embryo fibroblastic (AKR-2B) cells. Thus far, other colon carcinoma cell lines, some displaying TGF beta receptors, have been reported to be unresponsive to TGF beta. This study is therefore the first to demonstrate a TGF beta-responsive colon carcinoma cell line.
Hoosein
N M
NM
Brattain
D E
DE
McKnight
M K
MK
Levine
A E
AE
Brattain
M G
MG
D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003110:Colonic Neoplasms / Q000473:pathology*; D004126:Dimethylformamide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D010455:Peptides / Q000494:pharmacology*; D015291:Transforming Growth Factors; D014212:Tretinoin / Q000494:pharmacology
D005353:Fibronectins; D010455:Peptides; D014212:Tretinoin; D015291:Transforming Growth Factors; D004126:Dimethylformamide